Portal de Periódicos da CAPES

Toluene diisocyanate pulmonary disease: Immunopharmacologic and mecholyl challenge studies

1977; Elsevier BV; Volume: 59; Issue: 3 Linguagem: Inglês

10.1016/0091-6749(77)90153-1

1097-6825

Brian T. Butcher, John E. Salvaggio, Carol E. O’Neil, Hans Weill, O. P. Garg,

Occupational and environmental lung diseases

Selected workers exhibiting clinical "sensitivity' ' to toluene diiosocyanate (TDI) (wheezing, cough, and dyspnea upon entering a TDI-containing area) were studied for: (I) in vitro TDI-induced leukocyte histamine release; (2) determination qf cyclic 3',5' adenosine monophosphate (CAMP) levels of lymphocytes exposed to TDI; (3) effect of TDI on the isoproterenol-induced increase of lymphocyte CAMP levels; and (4) acetyl-pmethylcholine (mecholyl) inhalation challenge.TDI did not induce histamine release from leukocytes oj "sensitive"or "nonsensitive" individuals, nor were lymphocyte CAMP levels affected bJ in vitro TDI exposure.TDI did, however, diminish in vitro stimulation qf cAMP by isoproterenol.This @feet, seen with cells of "sensitive" and "nonsensitive" individuals, appeared to be dose-dependent; there were no significant differences between the two groups.When challenged with mecholvl, 7 qf 10 "sensitive" but only I qf 10 "nonsensitive" individuals showed a greater than 20% decrease in FEVI.These results suggest that TDI-induced obstructive airways disorders may be associated with altered P-adrenergic ,function.